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Objectives The goal of this study was to assess the mortality of hypertrophic cardiomyopathy (HCM), partly in times when
the disease was not elucidated and patients were untreated.
Background HCM is feared for the risk of sudden cardiac death (SCD). Insight in the natural history of the disorder is needed
to design proper screening strategies for families with HCM.
Methods In 6 large, 200-year multigenerational pedigrees (identified by using genealogical searches) and in 140 small
(contemporary) pedigrees (first-degree relatives of the proband) with HCM caused by a truncating mutation in
the myosin-binding protein C gene (n  1,118), we determined all-cause mortality using the family tree mortal-
ity ratio method. The study’s main outcome measure was the standardized mortality ratio (SMR).
Results In the large pedigrees, overall mortality was not increased (SMR 0.86 [95% confidence interval (CI): 0.72 to
1.03]), but significant excess mortality occurred between 10 and 19 years (SMR 2.7 [95% CI: 1.2 to 5.2]). In the
small families, the SMR was increased (SMR 3.2 [95% CI: 2.3 to 4.3]) and excess mortality was observed be-
tween 10 and 39 years (SMR 3.2 [95% CI: 2.3 to 4.3]) and 50 and 59 years (SMR 1.9 [95% CI: 1.4 to 2.5]).
Conclusions We identified specific age categories with increased mortality risks in HCM families. The small, referred pedi-
grees had higher mortality risks than the large 200-year multigenerational pedigrees. Our findings support the
strategy of starting cardiological and genetic screening in the first-degree relatives of a proband from 10 years
onward and including persons in the screening at least until the age of 60 years. Screening of more distant rela-
tives is probably most efficient between 10 and 19 years. (J Am Coll Cardiol 2011;58:2406–14) © 2011 by
the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.07.044Hypertrophic cardiomyopathy (HCM) is an autosomal
dominant disorder. The prevalence (1:500) is relatively
high, and HCM is the most common cause of sudden
cardiac death (SCD) in those age younger than 35 years and
in young athletes (1,2). The overall annual mortality rate of
the disease is approximately 1% (3-6).
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detected in the myosin-binding protein C (MYBPC3) gene
(7-11). Most of these mutations are nonsense or frameshift
mutations that are supposed to result in truncated proteins,
suggesting haploinsufficiency (9,12,13). Almost 25% of the
Dutch patients with HCM carry the c.2373dup (originally
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mutation in MYBPC3 (14). Initially, the phenotype of
YBPC3 mutation carriers was considered to be mild
15-18); however, there is increasing evidence that definite
enotype–phenotype correlations cannot be made. Hypertro-
hy and symptoms can develop at any age, and the clinical
ourse of the disease shows large variation: having a lifelong
symptomatic course is not an exception, but SCD at a young
ge, heart failure, and embolic stroke have also been observed
mong carriers of MYBPC3 mutations (8,19–21).
The identification of HCM-causing mutations has pro-
oted DNA-testing of probands and, subsequently, of
elatives. Family screening increasingly identifies asymp-
omatic carriers, who have an ill-defined mortality risk.
ccording to worldwide consensus, the risk of SCD in
CM patients and of asymptomatic mutation carriers
hould be assessed frequently on the basis of a small number
f readily determined clinical parameters (3). However,
raditional risk factor studies were mainly based on patients,
ot on individuals detected by family screening (22,23).
herefore, essential information is lacking to establish
eliable recommendations for follow-up, prophylactic inter-
entions in asymptomatic carriers, and to perform optimal
amily screening. Insight into the natural history of the
isorder is therefore needed to design proper cardiological
nd genetic screening strategies for families with HCM
24–28).
In the present study, we assessed the natural history with
he family tree mortality ratio (FTMR) method in large
ultigenerational pedigrees with untreated HCM patients
nd in a large number of small (contemporary) pedigrees (all
rst-degree family members of a proband) who visited 2
ertiary cardiogenetic clinics in the Netherlands (29,30).
ethods
ubjects and genealogical searches. We recruited a total
f 148 apparently unrelated consecutive HCM patients
probands) with a truncating MYBPC3 mutation who were
evaluated in the cardiogenetics/cardiovascular outpatient
clinics in the University Hospitals in Amsterdam and
Rotterdam between 1996 and 2009. A complete family
history was ascertained in 140 probands; for 8 probands, we
were unable to collect the date of birth and death of all
first-degree relatives. The identified mutations are described
in Table 1. Of these 140 patients, 94 (67%) were carriers of
the c.2373dup (p.Trp792ValfsX41) mutation. They all
shared an identical haplotype of the MYBPC3 gene, sug-
gesting a common founder approximately 25 generations
ago (14). We performed genealogical searches with the
official records of births, marriages, and deaths. These data
are very well preserved in the Netherlands and have been
collected irrespective of socioeconomic status starting 200
years ago. We traced maternal and paternal ancestors of the
probands throughout as many generations as possible, and
we were able to link 12 probands (with the c.2373dupmutation) to 6 pairs of common
ancestors. Subsequently, we traced
all first-degree relatives (50% car-
riers) of the persons on the trans-
mission line (obligate carriers)
and collected data on births and
deaths of these persons. We thus
collected 6 large, 200-year mul-
tigenerational pedigrees.
In addition, we collected data
on births and deaths of all first-
degree relatives of 140 probands
referred to our University Hospi-
tals. These small (contemporary)
pedigrees consisted of all first-
degree relatives of 94 probands with the c.2373dup mutation,
24 small families with the c.2827CT (p.Arg943X) mutation,
11 with the c.2864-2865delCT (p.Pro955ArgfsX95) muta-
tion, and 11 with different, other truncating mutations.
All probands were excluded. Furthermore, the parental
years lived before birth of mutation carriers were omitted to
avoid “reproduction” bias, as they must have been living
until this age to be able to transmit the mutation to their
offspring. The small and large pedigrees were constructed
out of the same pool of probands. Therefore, we excluded
the small pedigrees from the large pedigrees to avoid double
analyses of the same persons in the small and large pedigrees
as well as to avoid referral bias in the large pedigrees. The
first year of life of all individuals was omitted from our
analysis, as we know that registration of neonatal mortality
in the 19th century may have been incomplete.
All analyses ended at death, when a diagnosis of HCM
was made (and patients could have been treated for the
disease) or when the mutation was identified in the family
(and predictive testing became available, and treatment
could have been started). Furthermore, in a subsample of
the small pedigrees (62 pedigrees), we determined the cause
of death under the age of 40 years and the reason for referral
Different Truncating Mutations in theMYBPC3 GeneTable 1 Different Truncating Mutations in theMYBPC3 Gene
No. of
Identified
Mutations Mutation MYBPC3 n Type of Mutation
1 c.2373dup (p.Trp792ValfsX41) 94 Frameshift/truncating
2 c.2864-2865del(p.Pro955ArgfsX95) 11 Frameshift/truncating
3 c.2827CT (p.Arg943X) 24 Truncating
4 c.3776del (p.Gln1259ArgfsX39) 2 Frameshift/truncating
5 c.2893CT (p.Gln965X) 1 Truncating
6 c.3258dup (p.Lys1087GlufsX62) 1 Frameshift/truncating
7 c.932CA (p.Ser311X) 1 Truncating
8 c.897del (p.Lys301ArgfsX49) 2 Frameshift/truncating
9 c.676-701dup (p.Gly235Serfs74X) 1 Frameshift/truncating
10 c.989del (Pro330HisfsX20) 1 Frameshift/truncating
11 c.2149-?_2737? (pLys716fsX) 1 Frameshift/truncating
12 c.3181CT (p.Gln1061X) 1 Truncating
Abbreviations
and Acronyms
CI  confidence interval
FTMR  family tree
mortality ratio
HCM  hypertrophic
cardiomyopathy
MYPBC3  myosin-binding
protein C gene
SCD  sudden cardiac
death
SMR  standardized
mortality ratioTotal 140
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Mortality in HCM: Insight Into the Natural History November 29, 2011:2406–14Figure 1 Six Large Pedigrees With Carriers of the c.2373dup Mutation in the MYBPC3 Gene
Pedigree A consists of 49 persons; pedigree B, 38 persons; and pedigree C, 92 persons.
Continued on the next page.
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November 29, 2011:2406–14 Mortality in HCM: Insight Into the Natural HistoryFigure 1 Continued
Pedigree D consists of 34 persons; pedigree E, 60 persons; and pedigree F, 42 persons. The probands are indicated with an arrow. Solid squares/circles  100%
(obligate) male/female carriers; open squares/circles  male or female carriers with a 0.5 probability of carriership; semi-solid squares/circles  male or female carriers with
a 0.5 probability of carriership. The crossed of subjects have passed away. MYPBC3  myosin-binding protein C gene.
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to the study.
Statistical method (FTMRmethod). The mortality in the
large pedigrees and the small pedigrees (observed) was
compared with the mortality of the Dutch general popula-
tion (expected) standardized for age, sex, and calendar
period, as described previously (29). The expected mortality
was calculated by multiplying the total number of years lived
by the study population with the age- and sex-specific
mortality rates of the Dutch population for each calendar
period available at ‘Statistics Netherlands’ (31). The ratio of
observed to expected number of deaths is the standardized
mortality ratio (SMR). The 95% confidence interval (CI) of
the SMR was calculated assuming a Poisson distribution of
the observed number of deaths and by using exact limits.
Cumulative survival of subgroups was performed by using
Kaplan-Meier analyses and compared with Cox’s regression
(relative risk) using SPSS version 15.0.1 for Windows
(SPSS Inc., Chicago, Illinois). A p value 0.05 (2-sided)
was considered significant.
Results
Genealogical searches. We obtained 6 large pedigrees
with carriers of the c.2373dup mutation in the MYBPC3
gene (Fig. 1). We excluded 155 persons from these pedi-
grees: 12 probands, 104 first-degree relatives of these 12
probands, 28 persons because of missing date of birth or
death, and 11 persons who died before the age of 1 year. In
total, 160 persons (92 males, 68 females) of the 6 large
pedigrees were included in our analyses.
The 140 small families contained 965 first-degree rela-
tives (siblings, parents, and offspring) with a known date of
birth and death. After exclusion of the relatives who died in
the first year, 958 persons were included in our analyses (508
males, 450 females).
Mortalityriskinlarge200-yearmultigenerationalpedigrees. In
he 6 pedigrees, 130 deaths occurred in 9,129 person-years
etween 1811 and 2002 (when the mutation was detected)
mong 160 individuals with a (at least) 0.5 probability of
arrying the mutation. The mean SMR over that period was
.86 (95% CI: 0.72 to 1.03), meaning that there was no
verall excess mortality. However, significant excess mortal-
ty was observed in the age category of 10 to 19 years (SMR
.7 [95% CI: 1.2 to 5.2]) (Fig. 2). We subsequently
nalyzed this age category through the centuries: between
he periods 1804 to 1904 and 1904 to 2002, the SMR was
imilar: 2.8 (95% CI: 1.01 to 6.0) and 2.7 (95% CI: 0.6 to
.8), respectively.
ortality risk in small (contemporary) families. In the
140 small families, 241 deaths were observed in 37.233
person-years between 1897 and 2009 in 958 individuals
with a 0.5 probability of carrying a truncating MYBPC3
mutation. The mean SMR over this period was significantly
increased (SMR 1.5 [95% CI: 1.3 to 1.6]). cThe SMR was significantly increased between the ages of
10 and 19 years (SMR 2.5 [95% CI: 1.002 to 5.1]), 20 and
29 years (SMR 2.9 [95% CI: 1.5 to 5.1]), 30 and 39 years
(SMR 3.8 [95% CI: 2.4 to 5.6]), and 50 and 59 years (SMR
1.9 [95% CI: 1.4 to 2.5]) (Fig. 3A). Not unexpectedly, the
mortality of the c.2373dup mutation, accounting for the
majority of our patients, was roughly similar to the values
shown in Figure 3A (Fig. 3B).
Figure 4A reveals that survival in persons with a 0.5
probability of carrying the c.2373dup mutation in the small
families was not different from carriers of other truncating
MYBPC3 mutations (log-rank test, p  0.96). Females at
isk of a MYBPC3 mutation had a better survival than males
log-rank test, p  0.001) (Fig. 4B). The hazard ratio for
eath for males relative to females with a MYBPC3 muta-
ion was 2.0 (95% CI: 1.5 to 2.6; p  0.001) in a Cox
egression model.
We determined the cause of death in those aged
ounger than 40 years in a subsample of the small
edigrees (62 pedigrees). SCD occurred in 13 persons
59%), 8 died of other causes (mainly motor vehicle
ccidents), and 1 died of an unknown cause. We looked
or the reason of referral of the proband in 62 small
edigrees. Nineteen (31%) probands were referred be-
ause of HCM in the proband and SCD in the family.
he remaining 69% were referred because of HCM only.
iscussion
e studied the mortality of HCM, partly in times when the
isease was not recognized and patients were not treated.
he present-day physician faces an increasing need for such
ata on the natural history, because important decisions on
creening and treatment strategies have to be made for the
apidly growing number of asymptomatic HCM mutation
arriers coming to the attention of physicians.
The overall mortality in the large pedigrees was not
ncreased. Nonetheless, we identified an age category (10 to
9 years) during which the mortality risk was significantly
ncreased. We also studied smaller, contemporary families
ho were referred to our clinics because of HCM in the
roband and/or familial SCD. In these families, the SMR
as significantly increased from the age of 10 years until 60
ears, reaching a peak between 30 and 39 years. The SMRs
re based on persons with (at least) 0.5 probability of
arriership; therefore, mutation carriers will have higher
eported excess mortality risks.
One could argue that the difference in mortality risk
etween the small and the large pedigrees can be explained
y differences between the calendar periods. However, this
easoning is very unlikely because the excess mortality in the
arge pedigrees was consistent throughout the centuries.
lternatively, the type of mutation may explain the differ-
nces in mortality risk: the large pedigrees only consisted of
.2373dup mutation carriers whereas the small pedigrees
arried different MYBPC3 mutations. However, small fam-
p
a
H
o
o
p
H
h
w
p
fi
m
m
s
c
a
t
2
h
s
fi
t
g
o
a
o
h
t
a
m
o
i
w
w
h
l
t
A
(
l
S
2411JACC Vol. 58, No. 23, 2011 Nannenberg et al.
November 29, 2011:2406–14 Mortality in HCM: Insight Into the Natural Historyilies with the c.2373dup mutation and families with other
mutations had similar mortality risks (Figs. 3B and 4). A
lausible explanation for the differences between the small
nd the large pedigrees is that the persons in the large
CM pedigrees were included on the basis of transmission
f the mutation (based on Mendelian inheritance) and not
n their severe phenotype. The probands of the small
edigrees were referred to our clinics because of manifest
CM and in 31% of cases because of a positive family
istory for SCD (in the first-degree relatives). The latter
ill certainly lead to a bias toward more severely affected
ersons (included in the small pedigree analyses). This
nding is in line with previous HCM studies: the annual
ortality rate for death for HCM in early studies was esti-
ated at 4% to 6%, but later, larger, and more unselected
tudies reported lower mortality rates (approximately 1%) (27).
According to international and national HCM expert
onsensus, first-degree relatives of a patient with HCM are
dvised to seek cardiological surveillance from the age of 10
o 12 years (every 1 to 2 years until the age of 20 years; every
to 5 years until the age of 50 to 60 years) (3,32-34). The
igh mortality risks in the small families fully support this
trategy of starting cardiological and genetic screening in the
rst-degree relatives of a proband (with a MYBPC3 muta-
ion) from 10 years onward (accompanied with thorough
enetic counseling) until the age of 60 years. On the basis
f our data, we cannot give advice about the frequency
nd intensity (including risk stratification) of the cardi-
logical follow-up. The natural history of the disease is,
owever, best observed in the large pedigrees. Based on
hese results, screening of more distant relatives is prob-
bly most efficient between 10 and 19 years. Clearly,
ore research is required to identify the method with
0.01 
0.10 
1.00 
10.00 
1 - 9 10 - 19 20 - 29 3
S
M
R
Figure 2 Mortality Between 1811 and 2002 (6 Large Pedigree
of Carrying the c.2373dup Mutation in the MYBPC3 G
The mortality according to age categories is expressed in the standardized mortali
95% confidence intervals are depicted around the point estimates. MYPBC3  myptimal (cost-) effectiveness.Our finding of clear excess mortality in young age groups
n both the large and small pedigrees confirm that patients
ith a MYBPC3 mutation do not have a mild phenotype
ith a later onset of problems (19,21). We emphasize,
owever, that the increased mortality was certainly not
imited to adolescents and young adults but extended
hroughout a large period of life in the small families.
lthough this finding confirms observations by others
26,35,36), and it will guide family screening, we would still
ike to improve the identification of high and low risk of
CD among MYBPC3 mutation carriers. Therefore, future
research to identify genetic modifiers and other risk factors
is necessary. For instance, the present-day day high-
throughput sequencing techniques may offer potential im-
portant opportunities.
In the present study, females had a better survival than
males in the small families. Sex differences have been
described by others; females had a more age-related disease
progression, but no difference in HCM-related mortality
and death from any cause was observed (37). Other studies
in asymptomatic HCM mutation carriers reported males
having a higher probability of a clinical diagnosis of HCM
(22,23,28), and therefore possibly a higher risk of SCD.
Moreover, a study in transgenic mice found that male sex
aggravates the phenotype of HCM (38).
Study limitations. A potential limitation of our approach
is that the analyses were restricted to (truncating) mutations
in the MYBPC3 gene and can therefore not be generalized
to other HCM genes. However, mutations in the MYBPC3
gene account for a large proportion of the HCM population
worldwide, and most mutations in the MYBPC3 gene are, as
in our study, frameshift and nonsense truncating mutations
(9). As shown in Figure 4, we observed no differences in
40 - 49 50 - 59 60 - 69 70 - 109
ears
160 Persons With a 0.5 Probability
(SMR) and depicted as a point estimate.
inding protein C gene.0 - 39
y
s) in
ene
ty ratio
osin-bsurvival between the subjects with a c.2373dup mutation
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Mortality in HCM: Insight Into the Natural History November 29, 2011:2406–14and the other truncating mutations. It is likely that these
mutations share a common pathophysiological mechanism
(13), and that FTMR data on one of them are potentially
relevant to the vast majority of the MYBPC3 patients and
as such for approximately 30% of all patients with HCM.
For the large pedigrees, we collected data from death
certificates stored at municipal archives. In these certificates,
unfortunately only information about the lifespan was avail-
able, and only in a minority was the cause of death reported.
The reliability of this information is poor, which is under-
standable: in the 19th and beginning of the 20th century the
ability to make a diagnosis was difficult. Therefore, in the
large pedigrees, it is not possible to retrieve exactly whether
the increased mortality might have been related to the
mutation in the MYBPC3 gene. We acknowledge that this
lack of information is a weakness of our study. However,
Figure 3 Mortality in the Contemporary Small Families
(A) Mortality according to age category in 958 persons with a 0.5 probability of ca
(B) Mortality according to age category in 648 persons with a 0.5 probability of cafrom 62 small pedigrees, we determined the cause of deathin those aged younger than 40 years. SCD occurred in at
least 59% of all cases. In the general population, SCD in
those younger than 40 years is relatively rare (39,40) ,
accounting for 7% of deaths in the young in one study (40).
These data and data from the literature (26) indicate that
SCD caused the excess mortality in the individuals in our
small pedigrees under the age of 40 years and logically also
caused the excess mortality in our large pedigrees.
Conclusions
We quantified the risk for death in a large cohort of relatives
of HCM patients in times when the disease was not known
and patients were not treated and also in the contemporary
relatives of patients referred to our outpatient clinics. With
this unique way of studying the mortality of HCM, we
a truncating myosin-binding protein C (MYBPC3) mutation.
the c.2373dup mutation in the MYBPC3 gene.rrying
rryingidentified age windows of high mortality risks. Our findings
2413JACC Vol. 58, No. 23, 2011 Nannenberg et al.
November 29, 2011:2406–14 Mortality in HCM: Insight Into the Natural Historysupport the strategy of starting cardiological and genetic
screening in the first-degree relatives of a proband from 10
years onward and including persons in the screening at least
until the age of 60 years. Screening of more distant relatives
is probably most efficient between 10 and 19 years.
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